Back to Resource Center / Insights / Posted on 06-28-2024
The conversation around the cost and coverage of GLP-1 agonist (or GLP-1s) drugs for weight loss is one we frequently have with our clients. With less than 43% of employers covering these drugs for weight loss and major insurers and State Plans pulling back coverage due to cost, the financial implications are significant. However, the potential benefits of coverage extend beyond weight loss, including delaying or preventing other obesity-related comorbidities such as cardiovascular disease, diabetes, sleep apnea, arthritis, and cancer. Considering drug insurance coverage for obesity drugs requires a careful evaluation for businesses aiming to support employee health and manage long-term healthcare costs. While these drugs can help offer significant health benefits, you must weigh the financial implications, and ensure proper program support to maximize effectiveness and safety.
What is a GLP-1 agonist Drug?
Initially developed to help treat Type 2 diabetes, GLP-1 (Glucagon-Like Peptide-1) agonists play a crucial role in regulating blood sugar levels. These drugs mimic the GLP-1 hormone, naturally produced in the intestines, which plays several critical roles in blood sugar regulation. GLP-1 drugs help lower blood sugar and reduce appetite. They increase insulin, slow down how fast the stomach empties and can make users feel full, which helps with weight loss and managing diabetes. Because of their effectiveness in lowering blood sugar and their impact on weight loss, GLP-1 drugs have gained popularity for treating obesity, leading to their approval for weight loss by regulatory agencies like the FDA.
Risks and Implications
Prior Authorization
For organizations, instituting a pre-authorization requirement before blanketly covering weight-loss drugs is critical. It helps ensure the drugs are prescribed judiciously, aligning with the individual’s medical needs and overall treatment plan. This step promotes thoughtful decision-making, preventing unnecessary medication use and potential risks.
Consider the following criteria:
- Participants who qualify as obese based on specific BMI measurements must also have at least one additional, related health condition
- Participants commit to a structured weight management program, which includes behavior management coaching and nutrition counseling
- Participants are required to commit to essential lifestyle and behavior changes to receive the medication
- Quantity limits and day supply limits be instituted
Contrastingly, obesity, historically viewed as a lifestyle issue, has often been excluded from pharmacy benefit coverage by many plan sponsors. However, the rise of GLP-1s has prompted a reevaluation of this stance. The high cost of these medications complicates decision-making for employers, necessitating a balanced approach.
In this complex landscape, it’s vital for organizations to consider their employees’ well-being thoughtfully. Trusting the expertise of healthcare providers is paramount in navigating coverage decisions, ensuring that those genuinely in need of weight management support receive appropriate coverage and care.
Key Takeaways
The landscape of GLP-1s for weight management is evolving rapidly, prompting employers to reassess their strategies for obesity in the years ahead. Confronting the obesity epidemic is a long-term challenge that necessitates substantial cost and societal shifts. It will not happen without significant cost and social change. Considering drug insurance coverage for obesity drugs requires a thoughtful balance between potential health advantages and financial considerations.
Back to Insight Center
View More Insights
Why an Independent Consultant Changes the Value of a PBM Audit
Changing the conversation with the PBM Audits typically come with a heightened sense of anxiety and pressure for PBMs. When an independent consultant with no other PBM interests or alliances is involved, PBMs can be more certain the reporting is fair and credible. That dynamic can lead to more constructive conversations during data requests, dispute resolution, […]
Ethica Auditing Services: From Spreadsheets to Digital
Ethica’s PBM audit services Ethica’s digital-first approach supports a range of PBM audit services designed to validate contractual performance, uncover financial risk, and strengthen plan oversight, including: How the audit process works The exact audit timeline varies based on the audited organization and type of audit. Audited organizations frequently specify allowable response times in their […]
Medicare Part D Creditable Coverage: FSA, HRA and ICHRA Disclosures & 2027 Simplified Determination Method
On April 6, 2026, the Centers for Medicare & Medicaid Services (CMS) released final rules regarding Medicare Part D creditable coverage disclosures and determinations. Specifically, CMS eliminated the requirement for account-based plans, including Individual Coverage Health Reimbursement Arrangements (ICHRAs), to provide creditable coverage disclosures and finalized changes to the simplified method for determining a plan’s […]
View All +
Let’s make it make sense.
Pharmacy benefits clarity begins with our market analysis where we reveal data-driven insights and identify opportunities to help you make more informed decisions.